Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2005 by Hillel Yaffe Medical Center
Sponsor:
Collaborator:
Technion, Israel Institute of Technology
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00271141
First received: December 29, 2005
Last updated: NA
Last verified: December 2005
History: No changes posted
  Purpose

The proposed work is based on the detection of a novel molecule for sensitivity to oxidative stress in humans in venous blood


Condition
Parkinson's Disease
Oxidative Stress

Study Type: Observational
Study Design: Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Estimated Enrollment: 500
Study Start Date: May 2005
Estimated Study Completion Date: December 2015
Detailed Description:

Since alterations in mitochondrial functions in platelets and lymphocytes have been detected in Parkinson's disease we plan to monitor the metabolism a a new molecule (LTG) in the blood samples of Parkinson's disease patients and compare them to controls. We shall use 10 cc of venous blood and analyze serum, white blood cells and platelets. We shall not extract nor use DNA.The main purpose is to develop a marker for Parkinson's disease in venous blood.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Parkinson's disease Healthy control -

Exclusion Criteria:

None -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00271141

Contacts
Contact: Rivka Inzelberg, MD +972-4-6304607 inzelberg@hy.health.gov.il

Locations
Israel
Hillel Yaffe Medical Center Recruiting
Hadera, Israel
Principal Investigator: Rivka Inzelberg, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
Technion, Israel Institute of Technology
Investigators
Principal Investigator: Rivka Inzelberg, MD Hillel Yaffe Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00271141     History of Changes
Other Study ID Numbers: hy11/2005
Study First Received: December 29, 2005
Last Updated: December 29, 2005
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hillel Yaffe Medical Center:
Parkinson's disease
Oxidative stress
Marker

Additional relevant MeSH terms:
Disease Susceptibility
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Disease Attributes
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on November 25, 2014